Physician profile
Eva Volf
NPI 1124311857
$2,821.85
in general payments reported to CMS, 2019-2025
18 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $332 · 2021: $436 · 2022: $699 · 2023: $268 · 2024: $243 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.84 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $863.05 | 2019-2024 | |
| Abbvie INC. | $836.89 | 2019-2024 | Skyrizi |
| Janssen Biotech, INC. | $524.44 | 2019-2024 | Tremfya, Stelara, Simponi |
| Galderma Laboratories, L.P. | $85.37 | 2019-2021 | |
| Genentech USA, INC. | $73.04 | 2021-2022 | |
| Lilly USA, LLC | $71.12 | 2022-2025 | Ebglyss |
| Leo Pharma INC. | $64.19 | 2019-2022 | |
| Genzyme Corporation | $52.44 | 2024 | |
| Incyte Corporation | $47.99 | 2025 | Opzelura |
| Pfizer INC. | $41.51 | 2021-2022 | |
| Botanix Sb INC | $28.68 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $20.53 | 2023 | Sotyktu |
| Amgen INC. | $20.34 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.58 | 2021 | |
| Revance Therapeutics, INC. | $19.39 | 2025 | Daxxify |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $19.17 | 2021 | |
| Dermavant Sciences, INC. | $18.42 | 2023 | Vtama |
| Sun Pharmaceutical Industries INC. | $15.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Volf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.